Suppr超能文献

基于复杂天然产物合成的药物发现的里程碑。

A landmark in drug discovery based on complex natural product synthesis.

机构信息

Eisai Co., Ltd., Tokodai, Tsukuba-shi, Ibaraki, Japan.

Harvard University, Cambridge, Massachusetts, USA.

出版信息

Sci Rep. 2019 Jun 17;9(1):8656. doi: 10.1038/s41598-019-45001-9.

Abstract

Despite their outstanding antitumour activity in mice, the limited supply from the natural sources has prevented drug discovery/development based on intact halichondrins. We achieved a total synthesis of C52-halichondrin-B amine (E7130) on a >10 g scale with >99.8% purity under GMP conditions. Interestingly, E7130 not only is a novel microtubule dynamics inhibitor but can also increase intratumoural CD31-positive endothelial cells and reduce α-SMA-positive cancer-associated fibroblasts at pharmacologically relevant compound concentrations. According to these unique effects, E7130 significantly augment the effect of antitumour treatments in mouse models and is currently in a clinical trial. Overall, our work demonstrates that a total synthesis can address the issue of limited material supply in drug discovery/development even for the cases of complex natural products.

摘要

尽管它们在小鼠中具有出色的抗肿瘤活性,但从天然来源的有限供应限制了基于完整海鞘素的药物发现/开发。我们在 GMP 条件下以 >10 g 规模实现了 C52-海鞘素-B 胺(E7130)的全合成,纯度 >99.8%。有趣的是,E7130 不仅是一种新型的微管动力学抑制剂,而且还可以在药理学相关化合物浓度下增加肿瘤内 CD31 阳性内皮细胞并减少 α-SMA 阳性癌相关成纤维细胞。根据这些独特的作用,E7130 显著增强了抗肿瘤治疗在小鼠模型中的效果,目前正在进行临床试验。总的来说,我们的工作表明,全合成可以解决药物发现/开发中即使对于复杂天然产物的有限材料供应问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3abc/6572832/e283737e47fa/41598_2019_45001_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验